A decade of tamoxifen reduces BCa recurrence

December 13, 2012

Doubling the duration of adjuvant tamoxifen treatment in women estrogen receptor (ER)-positive breast cancer reduces risk of late recurrence and death compared with the current standard-of-care of 5 years' therapy. So say the results of a large international randomized trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium and simultaneously published in The Lancet.